University of California

Leland Stanford Junior University

Wisconsin Alumni Research Foundation

Michael A Gelman

Kevan M Shokat

Jeffrey S Glenn

Ingrid Choong

Brandon Tavshanjian

Samuel Helmer Gellman

Mark Smith

David M Lynn

Bernard Weisblum

Ronald Thaddeus Raines

Naoki Umezawa

Terra Potocky

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.

PI-kinase inhibitors with anti-infective activity

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.

Pi-kinase inhibitors with anti-infective activity

Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C-C)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.

Biocidal polymers

Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.

PI-kinase inhibitors with broad spectrum anti-infective activity

Disclosed are &#x3b2;-peptides and &#x3b2;-peptide conjugates that are capable of diffusing or otherwise being transported across the cell membranes of living cells. The &#x3b2;-peptides contain at least six &#x3b2;-amino acid residues, at leastsix of which are preferably &#x3b2;-homoarginine residues. It has been found that when pharmacologically-active agents are conjugated to these types of &#x3b2;-peptides, the resulting conjugates (also disclosed herein) are also capable of diffusing or otherwise being transported across the cell membranes of living cells, including mammalian cells.

Method for delivery of molecules to intracellular targets

Growing community of inventors

New York, NY, United States of America

Michael A Gelman